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ABSTRACT The aim of this review was to evaluate the clinical effectiveness of fractional exhaled nitric
oxide (FeNO) measured in a clinical setting for the management of asthma in adults.
13 electronic databases were searched and studies were selected against predefined inclusion criteria.
Quality assessment was conducted using QUADAS-2. Class effect meta-analyses were performed.
Six studies were included. Despite high levels of heterogeneity in multiple study characteristics,
exploratory class effect meta-analyses were conducted. Four studies reported a wider definition of
exacerbation rates (major or severe exacerbation) with a pooled rate ratio of 0.80 (95% CI 0.63–1.02). Two
studies reported rates of severe exacerbations (requiring oral corticosteroid use) with a pooled rate ratio of
0.89 (95% CI 0.43–1.72). Inhaled corticosteroid use was reported by four studies, with a pooled
standardised mean difference of −0.24 (95% CI −0.56–0.07). No statistically significant differences for
health-related quality of life or asthma control were found.
FeNO guided management showed no statistically significant benefit in terms of severe exacerbations or
ICS use, but showed a statistically significant reduction in exacerbations of any severity. However, further
research is warranted to clearly define which management protocols (including cut-off points) offer best
efficacy and which patient groups would benefit the most.
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Introduction
Asthma is a chronic disorder of the airways, caused primarily by inflammatory processes and
bronchoconstriction. Poorly controlled asthma can have a significant impact on the quality of life of the
affected individual and their family. An estimated 5.4 million people in the UK are currently receiving
treatment for asthma [1, 2]. Despite the high prevalence rates, deaths resulting from asthma are
uncommon.
The pharmacological management of asthma in adults aims to control symptoms (including nocturnal
symptoms and exercise induced asthma), prevent exacerbations and achieve the best possible lung
function, with minimal side-effects of treatment. Inhaled corticosteroids (ICSs) are the main treatment for
asthma, and although at low dosage the side-effects are few, high dosage or long-term use of ICS is
associated with an increased risk of systemic side-effects [3]. The current British guidelines on the
management of asthma recommend a stepwise approach, with escalation of medication until control is
reached or stepping down when control is good [4]. However, in certain cases there is suspected over- and
under-treatment.
Fractional exhaled nitric oxide (FeNO) is a noninvasive biomarker of airway inflammation in asthma. High
FeNO in the breath of patients with symptoms of asthma are correlated with eosinophilic airway
inflammation (a distinct corticosteroid responsive phenotype of asthma) [5–7]. The presence of
eosinophils may be used to direct treatment as patients without eosinophilic inflammation are thought to
be less responsive to ICS treatment [8]. Therefore, in order to reach a balance between treatment and
control, the addition of FeNO monitoring might allow optimisation of treatment in the different disease
phenotypes. Existing reviews of FeNO monitors suggest some benefits associated with FeNO [9–11];
however, none were statistically conclusive. In addition, these reviews focused on number of people with
an exacerbation, inappropriately included the cohort of pregnant women in the meta-analysis (pregnancy
can substantially affect the course of asthma) [12] and are out-of-date. To address these limitations we
have updated an existing review [9], with the addition of three new studies [13–16], to determine the
potential role of FeNO monitors in the management and monitoring of asthma in adults. This systematic
review was undertaken to inform a UK National Institute for Health and Care Excellence appraisal which
included an assessment of the use of the electrochemical FeNO monitors NIOX MINO (Aerocrine AB,
Solna, Sweden), NIOX VERO (Aerocrine AB) and NObreath (Bedfont Scientific Ltd, Maidstone, UK) in
the diagnosis and management of asthma [17, 18].
Methods
A systematic review was undertaken in accordance with the general principles recommended in the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement [19].
Data sources and searches
13 electronic databases and research registers were searched (including MEDLINE and the Cochrane
Library) between March and April 2013, with update searches conducted in September 2013 and
November 2014. Terms for NIOX VERO, a new FeNO device, were added to the strategy in August 2013.
The search strategy used free-text terms and subject headings for the tests (e.g. NIOX MINO, NObreath
and FeNO) combined with keywords for the condition (i.e. asthma or lower respiratory tract symptoms).
No language restrictions were applied. As part of updating an earlier systematic review [9], searches were
limited by date from 2009 (the last search date from the earlier review). Searches were supplemented by
hand-searching reference lists of relevant studies and contact with experts in the ﬁeld. Further details of
the search strategy are provided in the online supplementary appendix 1.
Study selection
All titles were examined for inclusion by one reviewer and any citations that did not meet the inclusion
criteria (e.g. non-human or unrelated to asthma) were excluded. All abstracts and full-text articles were
then examined independently by two reviewers. Any disagreements in the selection process were resolved
through discussion. Details of the selection criteria are provided in table 1. This review focuses on studies
relating to adults only. Details of FeNO for the management of asthma in children have been published
elsewhere (Timothy Gomersall, School of Health and Related Research, University of Sheffield, Sheffield,
UK; personal communication).
Data abstraction
Data relating to study design, patient characteristics and outcomes were extracted by one reviewer into a
standardised data extraction form and independently checked for accuracy by a second reviewer. Any
discrepancies were resolved through discussion. Where necessary, study authors were contacted for missing
information or additional data.
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Assessment of methodological quality
The methodological quality of each included study was assessed according to the Cochrane Collaboration’s
tool for assessing the risk of bias in randomised controlled trials (RCTs) [21]. The studies were assessed by
one reviewer and independently checked by another.
Data synthesis and analysis
Data were tabulated and discussed in a narrative review. Meta-analyses were planned, where appropriate,
to estimate a summary measure of effect on relevant outcomes using the methods documented in the
Cochrane Handbook [21, 22]. For rate outcomes, rates per person year were the preferred outcome metric,
as this accounts for multiple events in a single patient. The generic inverse variance method was used to
meta-analyse rate ratios using Review Manager software (Version 5.3. The Nordic Cochrane Centre, The
Cochrane Collaboration, 2014). For continuous outcomes, a standardised mean difference analysis was
conducted where outcomes were not reported in a standardised way. In all cases, fixed effects were used
first, and random effects applied if the I2 statistic indicated that heterogeneity was moderate or high. This
was judged to be the case at >40%. Studies in pregnant women were analysed separately as FeNO may be
affected by pregnancy [12].
TABLE 1 Study selection criteria
Inclusion Exclusion
Population Adults (⩾18 years) with diagnosis of
asthma including pregnant women.
Studies that included cohorts
with a mean age <18 years of age
Recruited patients were not
diagnosed with asthma
Animal models
Unselected specific population
(e.g. firefighters, obese or athletes)
Intervention Studies that measured FeNO according to the ATS 2005
criteria [20] for the management of asthma, either with
or without other indicators of asthma control. ATS criteria
relating to multiple testing were relaxed to allow
inclusion of studies that operated electrochemical devices
in line with the manufacturer’s instructions, which state
only one test is required. Studies where monitoring was
performed at home were excluded as this was not within
the scope of the assessment.
Device which is not validated for measuring FeNO
Offline measurements
Studies where FeNO is measured
on a more regular basis (i.e. not
during a routine annual review)
Comparator Studies comparing the intervention to any other
management strategy that does not utilise FeNO
measurements.
Includes the use of FeNO measurement as
part of the management strategy
Outcome Primary outcome of interest included incidence of acute
exacerbation (any definition of exacerbation severity was
acceptable, including “use of oral corticosteroids”),
inhaled corticosteroid use, unscheduled contact with
healthcare officials, hospitalisations and emergency
department visits expressed or calculable as rates per
person year or as the number of patients experiencing
exacerbations. These outcomes were chosen as they have
the greatest impact both clinically and economically.
Other outcomes included clinical complications
associated with acute exacerbation, asthma control and
symptoms, adverse events, health-related quality of life,
mortality and compliance.
Does not report data on FeNO-guided step-up/
step-down therapy
Measure of alveolar nitric oxide
or nasal nitric oxide
Study type Randomised controlled trials. Preclinical and biological studies
Editorials and opinion pieces
Studies only published in languages
other than English
FeNO: fractional exhaled nitric oxide; ATS: American Thoracic Society.
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TABLE 2 Study and population characteristics
First
author
[ref.]
Country, funding
details
Study design Inclusion/exclusion
criteria
Subjects
analysed/
recruited n/N
Age years Males n/N
(%)
Spirometry Severity FeNO Smokers;
Atopic;
Medication use
SMITH
[23]
New Zealand,
Mixed funding#
including
equipment
from Aerocrine
RCT: single blind,
single centre,
placebo-controlled
Chronic asthma [26]
managed in primary care;
regular ICS for
⩾6 months, no dose
change in previous
6 weeks. If could not
tolerate removal of LABA
during run-in allowed to
participate if could
tolerate a fixed dose.
Exclusions: ⩾4 courses oral
prednisone in previous
12 months; admission to
hospital for asthma in
previous 6 months; ever
admitted to IC for
asthma; smokers
(current or ex-) with a
history of >10 pack-years.
94/110
WBR: 13;
Intervention
group: 46/48
Control group:
48/49
Mean age
44.8 (range
12–73)
41/110
(37.3%)
Mean (range)
FEV1 % pred
Intervention
group:
86.4 (80.6–92.2)
Control
group: 83.1
(76.5–89.7)
Mean (95% CI)
symptom
score¶
Intervention
group: 0.6
(0.4–0.8)
Control
group:
0.8(0.6–1.1)
GM (95% CI)
FeNO 250 ml+
Intervention
group:
7.8 (6.6–9.3)
Control group:
6.4 (5.5–7.5)
Smokers: None
Atopic: NR
Medication use:
Bronchodilator use,
mean per day over
the previous
7 days (95% CI)
Intervention group:
0.5 (0.2–0.8)
Control group:
0.6 (0.3–0.8)
ICS use NR
SHAW
[24]
UK,
Asthma UK
grant, speakers
fees reported,
but not from
Aerocrine
RCT: single blind,
parallel group
GP diagnosis of asthma
with ⩾1 prescription for
anti-asthma medication
in the past 12 months.
Current nonsmokers with
a past smoking history of
<10 pack-years.
Exclusions: poorly
compliant; those with a
severe asthma
exacerbation (needing
prednisolone) in the
previous 4 weeks.
118 (ITT
LOCF)/119
WBR: 1
Intervention
group: 58
Control
group: 60
Adults
>18 years
Mean age NR
54/118
(46%)
Mean±SD
FEV1 % pred
Intervention
group:
81.4±20.9
Control group:
84.9±20.1
Mean±SD FEV1/FVC
Intervention
group:
71±10.7
Control group:
72±9.9
Mean±SD
Juniper
score
Intervention
group:
1.32±0.65
Control
group:
1.26±0.75
GM (68% CI)
log FeNO
Intervention
group: 29.2
(14.0–61.0)
Control
group: 31.2
(13.3–73.1)
Ex-smokers:
Intervention
group: 22%
Control group: 25%
Atopic:78 (66.1%)
out of 118
Medication use:
Mean±SD ICS
daily dose
Intervention group:
697±708 µg
Control group:
652±533 μg
SYK [14] Sweden,
Mixed funding#,
some from
Aerocrine
RCT: open label,
parallel group,
multicentre
Doctor’s diagnosis of
asthma and ICS
treatment for
⩾ 6 months, IgE
sensitisation to at least
one major airborne
perennial allergen.
Nonsmokers for ⩾1 year
and with smoking history
of <10 pack-years.
Patients all had mild to
moderate asthma.
165/187
WBR: 6
Intervention
group: 87/93
Control
group: 78/88
Adults
(18–64 years)
Mean±SD
41±12.4
94/181
(51.9%)
Mean±SD
FEV1 % pred
Intervention
group: 84.3±14.1
Control group:
83.7±12.5
Mean±SD
FEV1/FVC
Intervention
group: 0.78±0.08
Control group:
0.79±0.08
NR GM (95% CI)
FeNO ppb
Intervention
group: 22.0
(19.3–25.2)
Control
group: 21.6
(18.7–25.0)
Smokers: None
Atopic:165 (100%)
out of 165
Medication use:
Median (IQR)
budesonide
equivalent
ICS dose 400
(400–800) µg·day−1
LABA before study
entry 54 (30.0%)
out of 180
Continued
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TABLE 2 Continued
First
author
[ref.]
Country, funding
details
Study design Inclusion/exclusion
criteria
Subjects
analysed/
recruited n/N
Age years Males n/N
(%)
Spirometry Severity FeNO Smokers;
Atopic;
Medication use
CALHOUN
[13]
USA,
Mixed funding#,
equipment from
Aerocrine
RCT:
multiply-blinded,
multicentre
study
Mild to moderate
asthmatics, well
controlled persistent
asthma with compliance
rates ⩾75%, who could
tolerate treatment of two
puffs twice daily of
beclomethasone HFA
(40 μg·puff−1) during the
2 week run-in period
363 recruited
to trial
WBR: 21
Intervention
group:
115/115§
Control group:
114/114ƒ
Other study arm
(not included
in review):
113/113
Mean±SD:
Intervention
group:
34.8±11.3;
Control group:
34.2±11.9
75/229
(32.8%)
Mean±SD
FEV1 % pred
Intervention
group:
86.3±10.4
Control group:
87.7±12.1
Mean±SD
ACQ score
Intervention
group:
0.79±0.54
Control group:
0.72±0.50
Mean±SD AQLQ
score
Intervention
group:
6.16±0.77
Control group:
6.27± 0.76
Mean±SD ASUI
score
Intervention
group:
0.88±0.12
Control group:
0.90±0.10
GM±SD FeNO ppb
Intervention
group:
18.88±0.66
Control group:
21.38±0.62
Smokers: NR
Atopic:
196 (85.6%)
out of 229
Medication use:
Albuterol rescue
use median (IQR)
Intervention
group:
0.07 (0–0.43)
Control group:
0.04 (0–0.29)
HONKOOP
[16]
The Netherlands,
Mix of
non-commercial
grants and
funding from
Aerocrine
RCT; cluster design From protocol: doctor’s
diagnosis of asthma; who
need ICS as controller
medication (step 2–4
GINA guidelines); ICS
⩾3 months in the
previous year; no
exacerbation of asthma
within 1 month before
entry. Exclusions: daily or
alternate day oral
corticosteroid therapy for
at least 1 month before
entering into the study
611 randomised
Other data NR
Intervention
group:
189/205
Controlled
asthma:
219/232
Partly controlled
asthma:
203/210
Mean±SD age:
39.4±9.5
Intervention
group:
39.5±9.3
Controlled
asthma:
38.9±9.3
Partly
controlled
asthma:
39.9±9.8
190/611
(31%)
Intervention
group:
27.7%
Controlled
asthma:
31.6%
Partly
controlled
asthma:
34.2%
Mean±SD
FEV1 % pred
Intervention
group:
93.1±17.0
Controlled
asthma:
92.4±17.2
Partly controlled
asthma:
93.0±17.0
Mean±SD
ACQ score
Intervention
group:
0.99±0.73
Controlled
asthma:
1.08±0.84
Partly
controlled
asthma:
0.93±0.80
Mean±SD
FeNO ppb
Intervention
group:
24.5±21.7
Controlled
asthma:
27.3±30.4
Partly
controlled
asthma:
24.7±29.8
Smokers:
Intervention
group: 14%
Controlled
asthma: 13%
Partly controlled
asthma: 16%
Atopic: 322 (54%)
out of 611
Medication use:
LABA:
Intervention
group: 47%
Controlled
asthma: 49%
Partly controlled
asthma: 52%
Mean±SD
beclomethasone
equivalent dose:
Intervention
group: 853±642 μg
Controlled
asthma:
831±701 μg
Partly controlled
asthma: 825±639 μg
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TABLE 2 Continued
First
author
[ref.]
Country, funding
details
Study design Inclusion/exclusion
criteria
Subjects
analysed/
recruited n/N
Age years Males n/N
(%)
Spirometry Severity FeNO Smokers;
Atopic;
Medication use
Australia,
Mixed funding,
lecture fees
from Aerocrine
POWELL
[25]
RCT: double-blind,
parallel group,
multicentre
Doctor’s diagnosis
confirmed by respiratory
physician’s diagnosis of
asthma. Nonsmoking
pregnant women between
12 and 20 weeks
gestation with
doctor’s diagnosis
of asthma and who
were using inhaled
therapy in last year.
203/242WBR: 22
Intervention
group:
100/111
Control group:
103/109
Pregnant
adults
>18 years
Mean±SD
age 28±5.4
Mean (95% CI)
FEV1 % pred
Intervention
group: 95.1
(92.8–97. 4)
Control
group: 96.1
(93.5–98.7)
Mean (95% CI)
FEV1/FVC
Intervention
group: 79.7
(75.4–78.0)
Control
group: 80.63
(79.3–82.0)
0/220 (0%) Median
(IQR)
AQLQ-M
Intervention
group: 0.8
(0.4–1.5)
Control group:
1.0 (0.5–1.6)
Mean ACQ
score (read
off graph)
Intervention
group: 0.98
Control
group: 1.01
Median
(IQR) FeNO ppb
Intervention
group: 13.9
(6.6–32.0)
Control
group: 13.1
(7.5–24.0)
Ex-smokers:
80 (39.4%)
out of 203
Atopic: 156 (75.7%)
out of 206
Medication use:
Median (IQR) days
β2-agonist in the
past week
Intervention group:
1.0 (0–5)
Control group:
2.0 (0–6)
ICS users
Intervention group:
46 (41.4%) out of 111
Control group:
47 (43.1%) out of 109
Median (IQR) BDP
equivalent ICS dose
(µg per day)
Intervention group:
800 (400–800)
Control group: 800
(400–1600)
FeNO: fractional exhaled nitric oxide; RCT: randomised controlled trial; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; IC: intensive care; WBR: withdrew before randomisation;
FEV1: forced expiratory volume in 1 s; GM: geometric mean; NR: not reported; GP: general practitioner; ITT: intention to treat; LOCF: last observation carried forward; FVC: forced vital
capacity; IQR: interquartile range; ACQ: Asthma Control Questionnaire; AQLQ: Asthma Quality of Life Questionnaire; ASUI: Asthma Symptom Utility Index; GINA: Global Iniative for Asthma;
AQLQ-M; Asthma Quality of Life Questionnaire-Marks; BDP: beclomethasone dipropionate. #: mix of industry and non-industry funding, e.g. research council grants. ¶: daily score over the
previous 7 days. Asthma symptoms were scored for each 24-h period as follows: 0, indicated no symptoms; 1, symptoms for one short period; 2, symptoms for two or more short periods; 3,
symptoms most of the time that did not affect normal daily activities; 4, symptoms most of the time that did affect normal daily activities; and 5, symptoms so severe as to disrupt daily
activities. +: FeNO measured at 250 mL·s−1 gives lower values than FeNO at 50 mL·s−1. §: 37 withdrew, imputation method NR. ƒ: 13 withdrew, imputation method NR.
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Results
Trial flow
Of the 5354 citations identified, three RCTs [13, 14, 16] met the inclusion criteria and were added to the
three existing trials [23–25] identified in the previous systematic reviews [9, 11]. The majority of the
excluded articles did not use FeNO to guide step-up/step-down therapy or the study design was not an
RCT. A summary of the process of identifying and selecting the relevant literature can be found in online
supplementary appendix 2.
Characteristics of included studies
Table 2 presents the study characteristics of the six included studies [13, 14, 16, 23–25]. All the included
studies compared FeNO-guided asthma management to non-FeNO-guided management and all patients were
recruited in primary care, except for CALHOUN et al. [13], where the recruitment setting was unclear. The
device used to measure FeNO was not clearly reported in three studies. Most studies were of a small to
moderate size, with the number of patients ranging from 94 [23] to 611 [16]. All studies recruited adults of
either sex [13, 14, 16, 23, 24], apart from POWELL et al. [25], which recruited only pregnant women. The
comparability of study populations in terms of severity at baseline is difficult to determine as different scales
for severity and different metrics for medication use were reported. Inclusion and exclusion criteria suggest
that at least four studies [13, 14, 23, 25] recruited populations with mild to moderate asthma; while the other
two studies [16, 24] included a broader spectrum of severity. However, overall the patient population is
predominantly milder asthmatics (mean forced expiratory volume in 1 s (FEV1) range 81–96% predicted). In
addition, no studies followed the same timeline, visit frequency, management protocols, number and points
of FeNO cut-offs, and treatment doses varied across the included studies (table 3).
Risk of bias within studies
Table 4 summarises the methodological quality of the included studies. Generally, two studies [24, 25]
performed well receiving a positive assessment of at least six of the seven quality items. The most
frequently identified potential sources of a high risk of bias concerned “other biases” related to the receipt
of commercial funding (67%) [13, 14, 16, 23]. A high number of publications poorly reported the
following aspects: random sequence generation (33%) [13, 23], allocation concealment (33%) [13, 23] and
blinding of outcome assessment (50%) [13, 23, 24]. It should be noted that poor performance in quality
assessment for the study by SYK et al. [14] was due to its open label study design, which was necessary to
influence patients’ adherence to treatment and to capture these clinically valuable effects.
Outcomes and synthesis of results
Despite wide variation in all aspects of study design across the five studies [13, 14, 16, 23, 24] (excluding
the study on pregnant women) [25]; exploratory meta-analyses were conducted where possible for all
relevant outcomes (table 5).
Healthcare utilisation
Unscheduled healthcare utilisation, defined as emergency department/accident and emergency visits,
out-of-hours general practitioner’s surgery visits or hospitalisation, was only reported in HONKOOP et al.
[16]. Although the result showed improvement in healthcare utilisation with FeNO management (table 5),
this was not statistically significant for all comparisons (p>0.05). In the remaining four studies [13, 14, 23,
24], unscheduled healthcare utilisation was included as either treatment failure or severe exacerbations
(see later), since exacerbations of asthma can lead to both unscheduled healthcare utilisation and the need
for a course of oral corticosteroids (OCSs).
Severe exacerbations
This outcome was defined differently across studies (table 5). SYK et al. [14] and HONKOOP et al. [16]
defined it as “worsening requiring a course of OCS”; SHAW et al. [24] defined it as “exacerbations resulting
in the use of OCS or antibiotics”; and CALHOUN et al. [13] reported it as “exacerbations”, which included
exacerbations leading to OCS use, increased ICS use or additional medication for asthma. A meta-analysis
of four studies (the study of SMITH et al. [23] was not included as follow-up data were not calculable as
rates per person year) showed that severe exacerbations (while statistically not significant) were less likely
in the FeNO-guided-management group compared with the control group (figure 1a), with rate ratio of
0.80 (95% CI 0.63–1.02; p=0.08).
Severe exacerbations resulting in the use of OCS
Analysis of studies reporting the number of severe exacerbations resulting in the use of OCS (figure 1b)
was limited to only two studies [14, 16], which showed opposite directions of effect. This may be due to
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TABLE 3 Description of management strategies
First author
[ref.]
Basis for decisions Treatments indicated
Intervention Control Intervention Control
SMITH [23] FeNO, with a safety measure based on symptoms,
bronchodilator use and spirometry
FeNO <35 ppb (equivalent at 50 mL·s−1) defined
as controlled asthma
FeNO ⩾35 ppb defined as uncontrolled asthma
Safety measure: if one or more of the following
clinical criteria are met, increase one step:
1) Symptom score for previous 7 days ⩾1 point
more than mean during run-in and
minimum score of 2 out of 5
2) Nocturnal wakening on ⩾3 nights per week
more than mean during run-in
3) Mean daily bronchodilator use ⩾3 times
that of mean during run-in and minimum
use of 15 occasions during prior 7 days
4) Diurnal peak flow variation ⩾30% and/or
FEV1 of <85% of baseline
GINA 2002: symptoms,
bronchodilator use,
spirometer
Dose steps: placebo, inhaled fluticasone
100 µg, 250 µg, 500 µg, 750 µg and 1000 µg
Phase 1: until optimal dose reached
Phase 2: up titrate one step at a time; down
titrate if controlled for two visits, but not
lower than optimal dose
Patients had personalised self-management
plans, which instructed them to take oral
prednisone 40 mg per day when morning
peak flows fell below 70% of mean run-in
values, until it reached >85%, at which
time they took 20 mg per day for the
same number of days
As for intervention, but
without the personalised
management plan
SHAW [24] FeNO plus symptoms (Juniper score)
Exhaled nitric oxide <16 ppb on first occasion or
exhaled nitric oxide 16–26 ppb on second
occasion with
1) Juniper score ⩽1.57: step-down
anti-inflammatory treatment, step-down
bronchodilator treatment once off steroids.
2) Juniper score >1.57: step-down
anti-inflammatory treatment, step-up
bronchodilator treatment
Exhaled nitric oxide >26 ppb with
1) Juniper score ⩽1.57: step-up
anti-inflammatory treatment, no change
in bronchodilator treatment
2) Juniper score >1.57: step-up
anti-inflammatory treatment, step-up
bronchodilator treatment once on maximum
anti-inflammatory treatment
Safety measure: patients on 2000 µg
beclomethasone per day with >26 ppb FeNO
and had not fallen to 60% of baseline had
sputum checked. If no eosinophilic
inflammation, treatment reduced stepwise,
unless FeNO increased by >60% of baseline.
BTS/SIGN guidelines using
Juniper scale to score
symptoms:
1) treatment doubled
if score >1.57
2) treatment halved if
score <1.57 for
2 consecutive months
Hierarchy of anti-inflammatory treatment:
1) Low dose ICS (100–200 μg BDP
twice daily)
2) Moderate dose ICS (200–800 μg BDP
twice daily)
3) High dose ICS (800–2000 μg BDP
twice daily)
4) High dose ICS (800–2000 μg BDP
twice daily) plus LTRA
5) Higher dose ICS (2000 μg BDP
twice daily) plus LTRA
6) Higher dose ICS (2000 μg BDP
twice daily) plus LTRA plus oral
prednisolone 30 mg for 2 weeks, then
titrate the dose reducing by
5 mg·week−1
Hierarchy of bronchodilator treatment
1) SABA as needed
2) LABA
3) LABA plus theophylline
4) LABA plus theophylline plus nebulised
bronchodilator
Step 1: SABA as required
Step 2: Add ICS
200–800 μg·day−1
BDP equivalent
Step 3: Add inhaled LABA
Step 4: increase ICS up to
2000 μg·day−1 and
addition of fourth drug,
e.g. LTRA, theophylline
or LABA
Step 5: oral prednisolone,
high dose ICS, refer
to specialist care
Continued
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TABLE 3 Continued
First author
[ref.]
Basis for decisions Treatments indicated
Intervention Control Intervention Control
SYK [14] FeNO only
FeNO <19 ppb (men), <21 ppb (women):
decrease one step
FeNO 19–23 ppb (men), 21–25 ppb (women):
no change
FeNO ⩾24 ppb (men), ⩾26 ppb (women):
increase one step (no change in treatment step
if on step 4 or 5 and using ⩽2 inhalations of
short-acting β2-agonist per week)
FeNO ⩾30 ppb (men), ⩾32 ppb (women): increase
two steps (only if on treatment step 1)
Grey zone of 5 ppb applied to avoid frequent
dose changes
Symptoms, lung function,
β-agonist use (usual care)
Steps 1–6:
Budesonide (µg·day−1):
0, 200, 400, 800, 800+LTRA,
1600+LTRA
Fluticasone (µg·day−1): 0, 100,
250, 500, 500+LTRA,
1000+LTRA
Mometasone (µg·day−1):
0, 100, 200, 400, 400+LTRA,
800+LTRA
Assume same doses
as intervention
CALHOUN [13] FeNO only
Well controlled, FeNO <22 ppb: down one level
Controlled, FeNO 22–35 ppb: maintain level
Under-controlled, FeNO >35 ppb: up 1 level
NHLBI guidelines
(USA version of SIGN
guidelines)
Dosing beclomethasone HFA:
Level 1=0 μg per day
Level 2=80 μg once daily
Level 3=160 μg twice daily
Level 4=320 μg twice daily
Level 5=640 μg twice daily
As intervention
HONKOOP [16] ACQ and FeNO
Where ACQ ⩽0.75 with
1) FeNO ⩽25 ppb, step down
2) FeNO >25 ppb and <50 ppb, no change
3) FeNO ⩾50 ppb, step up
Where ACQ >0.75 and <1.50 with
1) FeNO ⩽25 ppb: and time <3 months,
no change, or change to LABA; if time
>3 months, step down ICS
2) FeNO >25 ppb and <50 ppb: step-up
(treatment choice)
3) FeNO ⩾50 ppb, step-up ICS by one level
Where ACQ ⩾1.50 with
1) FeNO ⩽25 ppb: step-up LABA
2) FeNO >25 ppb and <50 ppb: step-up
(treatment choice)
3) FeNO ⩾50 ppb: step-up ICS by two levels
ACQ scores
Strict strategy
ACQ ⩽0.75: <3 months,
no change; > 3 months,
step-down
ACQ >0.75 and <1.50:
Step-up: treatment choice
ACQ ⩾1.50: Step-up:
treatment choice
Sufficient strategy
ACQ ⩽0.75: Step-down
ACQ >0.75 and <1.50:
No change
ACQ ⩾1.50: Step-up:
treatment choice
Step 1: SABA as needed
Step 2: low-dose ICS; or LTRA
Step 3: low-dose ICS + LABA; or medium-
or high-dose ICS; or low-dose ICS+LTRA
Step 4: Add one or more of medium-
or high-dose ICS + LABA, and/or LTRA
Step 4: Add one or both of OCS (lowest dose),
anti-IgE treatment
As intervention for
both strategies
Continued
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TABLE 3 Continued
First author
[ref.]
Basis for decisions Treatments indicated
Intervention Control Intervention Control
FeNO concentration use to adjust dose of ICS
ACQ used to adjust dose of LABA
FeNO >29 ppb: ICS increase one step,
LABA no change
FeNO 16–29 ppb and ACQ ⩽1.5: ICS no change,
LABA no change
FeNO 16–29 ppb and ACQ >1.5: ICS no change,
LABA increase one step
FeNO <16 ppb and ACQ ⩽1.5: ICS decrease
one step, LABA no change
FeNO <16 ppb and ACQ >1.5: ICS decrease
one step, LABA increase one step
If a patient had undergone two ICS dose
increments and FeNO remained >29 ppb,
ICS was not increased further. If still
symptomatic (ACQ >1.5) formoterol 6 µg twice
daily was added. For patients taking formoterol,
the ICS dose could never be 0, but would be
reduced to 100 µg twice daily. Patients who
remained uncontrolled at maximum doses
were referred to a respiratory physician.
ACQ-guided
Well controlled asthma,
ACQ <0.75: reduce
treatment one step
Partially controlled asthma,
ACQ 0.75–1.50: no
treatment change
Uncontrolled asthma,
ACQ >1.5: increase one step
Those at maximum dose were
referred to a respiratory
physician
Steps 1–5
ICS: budesonide 0, 100, 200, 400 or
800 µg twice daily, respectively
LABA:
Step 1: salbutamol as required
Step 2–5: formoterol 6, 12, 24 or
24 µg twice daily, respectively
Step 1: salbutamol as
required
Step 2: budesonide 200 µg
twice daily plus
salbutamol as required
Step 3: budesonide 400 µg
twice daily plus
salbutamol as required
Step 4: budesonide 400 µg
and formoterol 12 µg
twice daily
Step 5: budesonide 800 µg
twice daily and
formoterol 24 µg
twice daily
FeNO: fractional exhaled nitric oxide; FEV1: forced expiratory volume in 1 s; GINA: Global Initiative for Asthma; BTS: British Thoracic Society; SIGN: Scottish Intercollegiate Guidelines
Network; ICS: inhaled corticosteroid; BDP: beclomethasone dipropionate; LTRA: leukotriene receptor antagonist; SABA: short-acting β2-agonist; LABA: long-acting β2-agonist; NHLBI:
National Heart, Lung and Blood Institute; ACQ: Asthma Control Questionnaire; OCS: oral corticosteroid.
POWELL [25]
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variations in the step-up/step-down protocols employed in the studies, or due to the populations being
slightly different.
Moderate and minor exacerbations
Two studies [14, 23] reported data on less severe exacerbations; however, this data was not amenable to
meta-analysis due to unreported data (table 5). Both studies observed lower rates of minor/moderate
asthma exacerbations in the intervention group compared with the control group. In SMITH et al. [23], the
rate was 0.36 versus 0.75 (p=0.24) and in SYK et al. [14], 0.1 versus 0.325 events per person year
respectively (p-value not reported).
Composite of all exacerbations and failure rates
Three studies reported composite outcomes that were considered to be broadly similar and represent what
may be termed “treatment failure” (table 5). In SMITH et al. [23] and SYK et al. [14] this was “any major or
minor exacerbation”, while in CALHOUN et al. [13] it was exacerbation or any loss of control by a variety of
measures. A meta-analysis of these studies (fig. 1c) showed a statistically significant effect in favour of
using FeNO-guided management in adults, with a rate ratio of 0.53 (95% CI 0.46–0.61; p<0.00001).
However, due to high degree of heterogeneity in composite outcomes, the effect is therefore liable to high
risk of bias.
ICS use
Four studies reported some data on ICS use [13, 14, 23, 24]; however, outcomes were not reported in a
standardised manner (table 5). As shown in figure 1d, a meta-analysis using the standardised mean
difference analysis showed a beneficial overall effect of −0.24 (95% CI −0.56–0.07) in favour of
FeNO-guided management; however, the findings were not statistically significant (p=0.13).
Relationship between ICS use, step-up/step-down protocol and exacerbations
A post hoc analysis was undertaken to examine the relationship between ICS use, exacerbations and which
step-up/step-down approach was used. A summary of the data is presented in table 6. Two studies that
used FeNO levels in conjunction with symptoms showed a statistically significant decrease in ICS use in the
FeNO-guided management groups and a nonsignificant decrease in any type of exacerbation [23, 24], thus
indicating improved management overall. By contrast, the studies which managed asthma based on FeNO
levels alone were less clear. SYK et al. [14] reported no change in ICS use and a nonsignificant decrease in
moderate exacerbation and a nonsignificant increase in severe exacerbation, but a significant decrease in
any exacerbation. CALHOUN et al. [13] reported no difference in ICS use and exacerbations.
Other outcomes
Health-related quality of life was infrequently reported. Three studies [13, 14, 16] used versions of the
Asthma Quality of Life Questionnaire to measure quality of life. Two studies showed no effect in the
global score (pooled standardised mean difference: 0.00 (95%CI −0.20–0.20); p=0.96) [13, 16]. However,
one study investigated domains and found a statistically significant difference in the symptoms score
(p=0.041) with a between group difference in change from baseline of 0.10 in favour of FeNO management
[14]. Asthma control was reported in all studies, but showed no statistically significant difference. Further
details on other outcomes are summarised in online supplementary appendix 3.
TABLE 4 Risk of bias summary: review authors’ judgements about each risk of bias item for each included study
First author
[ref.]
Methodological quality assessment: randomised controlled trials
Random sequence
generation
(selection bias)
Allocation of
treatment
concealed
Blinding of
participants and
personnel
Blinding of
outcome
assessment
Incomplete
outcome data
Selective
reporting
Other biases
(e.g. commercial
funding)
CALHOUN [13] U U L U U H H
HONKOOP [16] L L H H L L H
POWELL [25] L L L L L L U
SHAW [24] L L L U L L L
SMITH [23] U U U U L L H
SYK [14] L L H H L H H
L: low risk of bias; H: High risk of bias; U: unclear risk of bias.
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TABLE 5 Exacerbations and inhaled corticosteroid (ICS) use in adult patients with or without fractional exhaled nitric oxide (FeNO)-guided management
First author
[ref.]
Time of outcome Definition of outcomes Subjects n Exacerbations per
person year
Between group
comparison
ICS use Between group
difference#
SMITH [23] 3–12 months optimisation
(exacerbation rates
not reported for this
period) plus 12 months
titration
Minor: global daily asthma score¶
of two on ⩾2 consecutive days
94 Intervention
group+: 0.36
Control
group+: 0.75
p=0.24 Final value ICS use§
Intervention
Baseline: mean
411 μg per day
(95% CI 344–478)
End of phase 2:
mean 370 µg
per day
(95% CI 263–477)
Control
Baseline: mean
491 μg per day
(95% CI 403–579)
End of phase 2:
mean 641 µg
per day
(95% CI 526–756)
Mean difference
−270 µg per day
(95% CI −112–−430,
p=0.003)
Major: global daily asthma score¶
of three on ⩾2 consecutive days
(or in 1 day, in the context of a
minor exacerbation)
Major exacerbation or medical
emergency: global daily asthma
score¶ of four in 1 day
Intervention
group+: 0.13
Control
group+: 0.14
p=0.91
Any minor or major exacerbation Intervention
group: 0.49 (95%
CI 0.20–0.78)
Control group:
0.90 (95%
CI 0.31–1.49)
−45.6%
(95% CI −78.6–54.5,
p=0.27) NS
Course of oral prednisone Intervention
group: 0.48
Control group: 0.60
p=0.60
SHAW [24] 12 months Course of OCS or antibiotics 118 Intervention
group:
0.33 (SD 0.69)
Control group:
0.42 (SD 0.79)
−21% (95%
CI −57–43%, p=0.43)
Final value ICS useƒ
Intervention: 557 µg
Control: 895 µg
Mean difference
−338 µg per day
(95% CI −640–−37 µg,
p= 0.028)
Total used in
study (AUC):
11% greater in
FeNO group (95%
CI−15–37%)
SYK [14] End-points analysed
from visit 2 to visit
6 (2–4 weeks,
12 months)
Moderate exacerbation: need to
step-up controller treatment
for at least 2 days with or
without clinic visit
Prophylactic use before pollen
season excluded
165 Intervention
group: 0.1
Control
group: 0.325
NR ICS use¶¶
Intervention
Median 0
(IQR −400–400)
Baseline: mean
604 (SE 370)
Final value:
586 (SE 454)
Control
0 (IQR −200– 200)
Baseline: mean
626 (SE 391)
Final value:
540 (SE 317)
0.945
Severe exacerbation ##: worsening
requiring a course of OCS
Intervention
group: 0.113
Control group:
0.0875
NS
Moderate or severe exacerbation Intervention
group: 0.22
Control group: 0.41
p=0.024
Continued
12
D
O
I:10.1183/13993003.01882-2015
A
STH
M
A
|
M
.ESSAT
ET
A
L.
TABLE 5 Continued
First author
[ref.]
Time of outcome Definition of outcomes Subjects n Exacerbations per
person year
Between group
comparison
ICS use Between group
difference#
CALHOUN [13] 9 months Exacerbation: unscheduled medical
contact for increased asthma
symptoms that results in the use
of OCS, increased ICS or
additional medication for asthma
229 Intervention group:
0.21 (97.5%
CI 0.1–0.32)
Control group:
0.23 (97.5%
CI 0.1–0.37)
“Did not differ” ICS use (unclear if
mean over whole study
or final value)ƒ
Intervention
Mean 1617 µg·month−1
Control
Mean 1610 µg·month−1
NR
Treatment failure defined as
exacerbation or loss of control++
Intervention group:
0.27 (97.5% CI
0.14–0.39)
Control group:
0.43 (97.5% CI
0.23–0.64)
“Were not different”
HONKOOP [16] 12 months Severe exacerbation: course of oral
prednisone, hospitalisation
and/or emergency
department visit
611 Intervention group:
0.19 (95%
CI 0.11–0.29)
Control group
Strict: 0.29 (95%
CI 0.17–0.40)
Sufficient: 0.29
(95% CI
0.15–0.43)
Odds ratio versus
Strict: 0.64 (95%
CI 0.27–1.56)
Sufficient: 0.79
(95% CI 0.32–1.92)
NR NR
Unscheduled healthcare utilisation:
hospitalisation and/or emergency
department visit
Number of visits
Intervention
group: 3
Controlled asthma:
strict 5
Partly controlled
asthma:
sufficient 9
Odds ratio versus
Strict: 0.61 (95%
CI 0.14–2.58)
Sufficient:
0.37 (95%
CI 0.10–1.38)
NS: nonsignificant difference; OCS: oral corticosteroid; AUC: area under curve; NR: not reported; IQR: interquartile range; PEFR: peak expiratory flow rate. #: Expressed as intervention
minus control (negative values indicate lower FeNO). ¶: Asthma scores were as follows. 0 (stable): morning PEFR >75% of best PEFR in 14-day run-in period without deterioration in any
symptom scores. 1 (mildly unstable): one or more of the following a) bronchodilator use on two or more occasions in 24 h more than the rounded mean number of occasions during the
run-in period; b) increase in symptom score of 1 point or more as compared with rounded mean during run-in period; c) onset of or increase in nocturnal waking by one or more times in
the previous seven nights more than rounded mean number of times during the run-in period, or morning PEFR of 61–75% without deterioration in any of the above categories. 2 (minor
deterioration): morning PEFR of 61–75% of best PEFR during the run-in period and one or more criteria for an asthma score of 1; or morning PEFR of 41–60% without deterioration in
any criteria for an asthma score of 1. 3 (major deterioration): morning PEFR of 41–60% of best PEFR during run-in period and one or more criteria for an asthma score of 1. 4 (major
exacerbation or medical emergency): morning PEFR of 40% or less than best PEFR during run-in period regardless of symptoms, or attendance at clinician’s office or emergency
department because of severe asthma. +: Estimated off graph. §: Fluticasone or the equivalent. ƒ: Beclomethasone diproprionate or equivalent. ##: American Thoracic Society/European
Respiratory Society Task Force Criteria 2009. ¶¶: Budesonide equivalent. ++: At-home measurements: 1) Pre-bronchodilator AM peak expiratory flow (PEF) of <65% of baseline on two
consecutive mornings, scheduled measurements. 2) Post-bronchodilator PEF of <80% of baseline despite 60 min of rescue β-agonist treatment. 3) Post-bronchodilator PEF may be taken
at any time of day, an increase in albuterol use of more than 8 puffs per 24 h over baseline use for a period of 48 h, or more than 16 puffs per 24 h for more than 48 h. In-clinic
measurements: 1) Pre-bronchodilator forced expiratory volume in 1 s (FEV1) values on two consecutive sets of spirometric determinations, measured 24–72 h apart, that are <80% of the
baseline pre-bronchodilator value (baseline value for adherence period: FEV1 value at visit 3; baseline for randomisation period: FEV1 value at visit 4). All participants found to have an
FEV1 of <80% of baseline at any centre visit but who are not considered to meet treatment failure or exacerbation criteria must be seen again within 72 h to have FEV1 measured. 2)
Physician judgment for patient safety. 3) Patient dissatisfaction with asthma control achieved by study regimen. 4) Requirement for open-label ICSs or another (nonsystemic
corticosteroid) new asthma medication (e.g. montelukast) without the addition of systemic corticosteroids.
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Efficacy of FeNO in pregnant women
One study reported the efficacy of FeNO-guided management of asthma in pregnant women [25]. The
composite outcome of all exacerbations was statistically significantly reduced in the intervention arm, with
an incidence rate ratio of 0.496 per pregnancy (95% CI 0.325–0.755; p=0.001). This difference was mostly
driven by the rate of OCS use and the rate of doctors’ visits during pregnancy (table 7). Mean OCS use in
the FeNO and control arm was 0.08 (95% CI 0.03–0.133) and 0.19 (95% CI 0.08–0.31), respectively
d)
Study or subgroup
CALHOUN [13]
SHAW [24]
SMITH [23]
Heterogeneity, Tau2=0.08; Chi2=11.11, df=3 (p=0.01); I2=73%
Total (95% CI)
Test for overall effect Z=1.51 (p=0.13)
Experimental
1.617±1.000
557±835.7726
370±360.3138
Mean±SD Total
115
58
48
Std. mean difference 
i.v., random (95% CI)
0.01 (–0.25–0.27)
–0.40 (–0.77– –0.04)
–0.71 (–1.13– –0.28)
SYK [14] 586±4234.6301 87
306
Mean±SD
Control
1.610±1.000
895±836.7725
641±356.0468
540±2799.6682
Total
114
60
48
78
300
Weight %
28.2
23.8
21.7
26.3
100.0
0.01 (–0.29–0.32)
–0.24 (–0.56–0.07)
Std. mean difference
i.v., random, 95% CI
Study or subgroup
a)
CALHOUN [13]
HONKOOP [16]
SHAW [24]
SYK [14]
Heterogeneity, Tau2=0.03; Chi2=10.77, df=3 (p=0.01); I2=72%
Total (95% CI)
Test for overall effect Z=1.77 (p=0.08)
log
(rate ratio)
–0.09097178
–0.41726314
–0.24116206
0.25762178
SE
0.45116134
0.0476771
0.0917899
0.22857143
Weight %
6.3
41.1
35.2
17.4
Rate ratio 
i.v. random (95% CI)
0.91 (0.38–2.21)
0.66 (0.60–0.72)
0.79 (0.66–0.94)
1.29 (0.83–2.03)
100.0 0.80 (0.63–1.02)
Rate ratio 
i.v., random, 95% CI
0.01
Favours
FeNO-guided
Favours
control
0.1 1 10 100
0–1–2
Favours
experimental
Favours
control
1 2
c)
CALHOUN [13]
SMITH [23]
SYK [14]
Heterogeneity, Tau2=0.00; Chi2=0.38, df=2 (p=0.83); I2=0%
Total (95% CI)
Test for overall effect Z=8.34 (p<0.00001)
log
(rate ratio)
–0.46536325
–0.60798937
–0.65112175
SE
0.2943
0.34988064
0.0811328
Weight %
6.7
4.8
88.5
Rate ratio 
i.v. random (95% CI)
0.63 (0.35–1.12)
0.54 (0.27–1.08)
0.52 (0.44–0.61)
100.0 0.53 (0.46–0.61)
Study or subgroup
Rate ratio 
i.v., random, 95% CI
0.01
Favours
FeNO-guided
Favours
control
0.1 1 10 100
b)
Heterogeneity, Tau2=0.20; Chi2=8.35, df=1 (p=0.004); I2=88%
Total (95% CI)
Test for overall effect Z=0.35 (p=0.73)
Test for subgroup differences: Not applicable
100.0 0.89 (0.43,1.72)
Study or subgroup
HONKOOP [16]
SYK [14]
Heterogeneity, Tau2=0.20; Chi2=8.35, df=1 (p=0.004); I2=88%
Test for overall effect Z=0.35 (p=0.73)
log
(rate ratio)
–0.41726314
0.25762178
SE
0.0476771
0.22857143
Weight %
55.5
44.5
Rate ratio 
i.v. random (95% CI)
0.66 (0.60–0.72)
1.29 (0.83–2.03)
Subtotal (95% CI) 100.0 0.89 (0.46–1.72)
Rate ratio 
i.v., random, 95% CI
0.01
Favours 
FeNO-guided
Favours
control
0.1 1 10 100
FIGURE 1 Random effects meta-analysis. a) Effects of fractional exhaled nitric oxide (FeNO)-guided asthma management on major/severe
exacerbation rates. b) Number of severe exacerbations resulting in the use of oral corticosteroids. c) Effects of FeNO-guided asthma management
on the composite outcome of all exacerbation and treatment failure rates. d) Effects of FeNO-guided asthma management on mean inhaled
corticosteroids use (standardised mean difference analysis).
14 DOI: 10.1183/13993003.01882-2015
ASTHMA | M. ESSAT ET AL.
(p=0.042). Similarly, the rate of doctors’ visits was 0.26 (95% CI 0.16–0.36) in the FeNO arm and 0.56
(95% CI 0.40–0.72) in the control arm with a p-value of 0.002 in favour of FeNO management. Other
components of the exacerbation outcome (hospitalisations and emergency room/labour ward visits) did
not differ between groups. The change in mean value from baseline to final visit for ICS use decreased by
210 µg·day−1 in the intervention arm and increased by 50 µg·day−1 in the control arm. The difference was
statistically significant in favour of FeNO management (p=0.043). However, overall more patients received
ICS (68% versus 42%) in the FeNO group than in the control group by the end of the study. Other
outcomes are summarised in table 7.
Discussion
In this systematic review, six RCTs were identified that assessed the use of FeNO for the management of
asthma in adults [13, 14, 16, 23–25]. In general, using exploratory meta-analysis, a fall in exacerbation
rates per person year were observed, but none were statistically significant apart from the composite of all
exacerbations and failure rates. However, the findings should be interpreted with caution due to the high
degree of heterogeneity in the outcome definition. The effects on ICS use were heterogeneous, although
the direction of the effect was towards a decrease in ICS use. The effect on healthcare utilisation was not
statistically significant; however, as this outcome was only reported in one low quality study [16], to base
any conclusion on this could be misleading. The use of FeNO to guide asthma management in pregnant
women in the second trimester appears to be as effective, if not more so, than in other adults [25], and
appears to reduce exacerbations and ICS use, but by the end of the study more patients in FeNO group had
received ICS. The differences in outcome between studies may have occurred due to some step-up/
step-down protocols being better at decreasing ICS use than others, or may be due to the characteristics of
the study populations. Other potential factors as to why the FeNO monitoring studies have been
predominately negative could be due to the difference in severity of asthma at baseline, different treatment
strategies used (i.e. some studies controlled only ICS while some also controlled other medications),
differences in the number and points of FeNO cut-off used, and also the comparator groups did not all use
the same algorithm.
There are at least two previous systematic reviews on the effectiveness of FeNO monitoring to guide
management [9, 11]. PETSKY et al. [9] compared adjustments of asthma therapy based on FeNO with
conventional methods (typically clinical symptoms and spirometry). The review suggested some benefits
associated with FeNO for several outcomes, in particular the number of subjects with >1 exacerbation,
exacerbation rates, FEV1 % predicted at final visit and geometric change in FeNO from baseline; however,
none of these results were statistically conclusive. FeNO appeared to have some beneficial effect on
symptom score (mean difference: −0.14, 95% CI −0.42–0.14) and lowered ICS dose (mean difference:
−450.03 μg, 95% CI −676.73–−223.34 μg). Furthermore, there was substantial clinical heterogeneity
among the study cohorts, with no two studies using exactly the same step-up/step-down protocols. There
TABLE 6 Relationship between inhaled corticosteroid (ICS) use, step-up/step-down protocol and exacerbations
Frist author
[ref.]
Management
plan
Severity of
population
Treatment Atopic Exacerbation ICS use
Any Major Minor
SMITH [23] FeNO +
symptom-based
safety protocol
Excluded
severe
ICS NR NS decrease NS decrease NS decrease SS decrease
SHAW [24] FeNO +
symptoms
Recent severe
exacerbations
excluded
ICS, LTRA,
bronchodilator
66% NR NS decrease NR SS decrease
SYK [14] FeNO only Mild to
moderate
ICS, LTRA 100% SS decrease NS increase NS decrease
(moderate)
No change
CALHOUN [13] FeNO only Mild to
moderate
ICS 86% No change No change NR No change
HONKOOP [16] FeNO +
symptoms
Excluded
those taking
OCS every
day/every
other day
ICS, SABA,
LABA, LTRA,
OCS
54% NR NS decrease NR NR
FeNO: fractional exhaled nitric oxide; NR: not reported; NS: nonsignificant; SS: statistically significant; LTRA: leukotriene receptor antagonist;
OCS: oral corticosteroid; SABA: short-acting β2-agonist; LABA: long-acting β2-agonist.
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is some agreement between the review by PETSKY et al. [9] and our own review, especially relating to the
lack of statistically significant effects in most outcomes. The strength of our review lies in the inclusion of
subsequently published studies (CALHOUN et al. [13], SYK et al. [14] and HONKOOP et al. [16]), the focus on
exacerbation rates rather than number of people with an exacerbation, and the prior separation of
pregnant women into a different subgroup. The second review by DONOHUE and JAIN [11] updated the
meta-analyses of the number of patients with >1 exacerbation and exacerbation rates from the
aforementioned Cochrane review [9], and included a study in pregnant women [25]. Inclusion of this
study resulted in improvements on all measures of exacerbations (mean difference: −0.27, 95% CI −0.42–
−0.12), and the relative rate of asthma exacerbations (relative rate: 0.57, 95% CI 0.41–0.80). However, since
it is known that pregnancy can substantially affect the course of asthma [12], it was arguably inappropriate
to include the cohort of pregnant women in a meta-analysis of adults with asthma.
One of the putative benefits of using FeNO for the management of asthma is the identification of patients
for whom increased ICS use will not improve control. These patients are likely to present with symptoms,
which would indicate an increase in pharmaceutical management under standard clinical guidelines, and
under most of the FeNO protocols that have been studied to date, whereas they may be better treated with
other asthma control medications. A key limitation is therefore the paucity of studies that allowed
step-down of ICS to be performed on the basis of low FeNO values alone. Only two studies [13, 14] and
the study in pregnant women [25] included such a strategy, and only POWELL et al. [25] made provision
for adjusting other treatments which may offer superior control in these patients in response to their
reported symptomatology. We did not plan or perform a sensitivity analysis of this data, but did present a
rudimentary analysis of the relationship between ICS use, management protocols and exacerbations
(table 6). It is interesting to note that the two studies that managed patients on the basis of FeNO only
(SYK et al. [14] and CALHOUN et al. [13]) did not report any change in ICS use, which is perhaps contrary
TABLE 7 Pregnant women: all outcomes
Time of
outcome
Definition of outcomes Intervention Control Between group
comparison
Exacerbations# Exacerbations: an unscheduled visit
to a doctor, presentation to the
emergency room or admission
to hospital, or when OCS used
Events separated by 7 days or more
were counted as a second event
0.288 per pregnancy
(mean±SD study time
17.8±5.5 weeks)
0.615 per pregnancy
(mean study time
18.8±3.8 weeks)
Incidence rate
ratio 0.496 (95%
CI 0.325–0.755),
p=0.001
Mean (95% CI) OCS use 0.08 (0.03–0.133) 0.19 (0.08–0.31) p=0.042
Mean (95% CI) hospitalisations 0 (0–0) 0.03 (−0.004–0.06) p=1.0
Mean (95% CI) emergency
room/labour ward visits
0.04 (0.001–0.07) 0.02 (−0.01–0.04) p=0.399
Mean (95% CI) unplanned or
unscheduled doctors’ visits
0.26 (0.16–0.36) 0.56 (0.40–0.72) p=0.002
ICS use Difference in means (from baseline
to last visit) (read off graph):
−210 µg·day−1 50 µg·day−1 p=0.043
Median (IQR) BDP equivalent
ICS dose (µg·day−1)
200 (0–400) 0 (0–800) p=0.079
Users 76 (68.5%) out of 111 46 (42.2%) out of 109 p<0.0001
Other outcomes Median (IQR) HRQoL
SF-12 physical summary
(low 0, high 100):
47.7 (40.8–52.0) 46.9 (38.2–51.8) p=0.89
SF-12 mental summary
(low 0, high 100):
56.9 (50.2–59.3) 54.2 (46.1–57.6) p=0.037
AQLQ-M: total score
(good 0, poor 10):
0.75 (0.38–1.25) 0.81 (0.38–1.63) p=0.54
Asthma control: mean±SD ACQ 0.56±0.67 0.72±0.80 p=0.046
Median (IQR) β2-agonist use
in past week
0 (0–3) 1 (0–5) p=0.024
LABA users 45 (40.5%) out of 111 19 (17.4%) out of 109 p<0.0001
Adverse events, mortality,
compliance and test failure rates
NR NR NR
OCS: oral corticosteroids; IQR: interquartile range; BDP: beclomethasone diproprionate; ICS: inhaled corticosteroid; HRQoL: health-related
quality of life; SF-12: short form 12; AQLQ-M: Asthma Quality of Life Questionnaire-Marks; ACQ: Asthma Control Questionnaire; LABA:
long-acting β2-agonist; NR: not reported.
#: time of outcome was monthly until birth (maximum ∼30 weeks). Information from [25].
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to expectations, or in severe exacerbations. However, SYK et al. [14] did report a fall in exacerbations
overall. In comparison, the two studies that managed patients on the basis of FeNO and symptoms (SMITH
et al. [23] and SHAW et al. [24]) reported a statistically significant decrease in ICS use and a nonsignificant
decrease in exacerbations. This perhaps indicates a shift in treatment patterns, with better targeting of
treatment with the addition of FeNO to the patients who will benefit most. In addition, although there was
no significant difference in compliance with treatment between the FeNO management and control group,
there is a potential that FeNO may help improve compliance with ICS use.
There are a number of limitations to our review which warrant caution in its interpretation to clinical
practice. The evidence from the included studies are of low quality and there is significant heterogeneity in
all aspects of study design across the studies, including patient characteristics, outcome definitions, FeNO
cut-off points and in management protocols, hence an exploratory meta-analysis was used to overcome
these differences. In addition, the management plan used in some studies did not reflect real life practice,
for example in the study by SMITH et al. [23], long-acting β2-agonist (LABA) was not used and patients
underwent a step-down therapy approach in the pre-study phase. It is noteworthy that LABA in
combination with ICS are key steps in asthma management. The equivalence of devices is assumed and
this may not hold true in practice. As such, FeNO cut-off values as reported in the primary research may
not be applicable to measurements using other devices. Smoking affects FeNO levels and majority of
the patients in this review were nonsmokers, hence it is not clear if the results can be generalised to the
smoking population. Also, the average age of patients in this review was around 40 years old. However, the
majority of asthma deaths occur in older people with severe disease. All the included studies recruited
patients that were stable during the run-in period and excluded the more severe/difficult patients with
recent hospital admissions. So, by definition, some of the real life “difficult” patients, who require more
help, were excluded. Finally, the criteria used for the diagnosis of asthma across the included studies varied
with limited data and as recent studies have reported the potential of overdiagnosis of asthma, this may
have implications for the results. It is important to note that these limitations are principally sourced in
the evidence base, rather than the methods used to interrogate and evaluate it. One should also bear in
mind that the addition of FeNO to the current management strategy will require change in organisation
and to the philosophy of care in self-management.
Conclusion
FeNO guided management showed no statistically significant benefit in terms of severe exacerbations or
ICS use, but showed a statistically significant reduction in exacerbations of any severity. Due to
heterogeneity in the studies it was not possible to draw any firm conclusions as to which management
protocol or cut-off points offer the best efficacy. Further research is required to investigate the best way to
use FeNO in the management of asthma, which management protocol and cut-offs to use; to establish
which patient groups are likely to benefit from FeNO monitoring, e.g. individuals with atopy, frequent
exacerbations or those with poor adherence; and how treatment effect will progress over time. Larger,
well designed RCT studies, taking into account issues such as severity as defined by previous
exacerbations, blinding and approximating to routine care are warranted to clearly define the role of FeNO
in clinical practice.
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